GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (XTER:MDG1) » Definitions » Total Liabilities

Medigene AG (XTER:MDG1) Total Liabilities : €10.65 Mil (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Medigene AG Total Liabilities?

Medigene AG's Total Liabilities for the quarter that ended in Dec. 2023 was €10.65 Mil.

Medigene AG's quarterly Total Liabilities declined from Dec. 2022 (€14.65 Mil) to Jun. 2023 (€11.99 Mil) and declined from Jun. 2023 (€11.99 Mil) to Dec. 2023 (€10.65 Mil).

Medigene AG's annual Total Liabilities declined from Dec. 2021 (€14.65 Mil) to Dec. 2022 (€14.65 Mil) and declined from Dec. 2022 (€14.65 Mil) to Dec. 2023 (€10.65 Mil).


Medigene AG Total Liabilities Historical Data

The historical data trend for Medigene AG's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigene AG Total Liabilities Chart

Medigene AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.39 21.60 14.65 14.65 10.65

Medigene AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.65 17.36 14.65 11.99 10.65

Medigene AG Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Medigene AG's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.179+(2.036+1.434
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=10.65

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=31.716-21.067
=10.65

Medigene AG's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.179+(2.036+1.434
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=10.65

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=31.716-21.067
=10.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medigene AG Total Liabilities Related Terms

Thank you for viewing the detailed overview of Medigene AG's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigene AG (XTER:MDG1) Business Description

Traded in Other Exchanges
Address
Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.

Medigene AG (XTER:MDG1) Headlines

No Headlines